Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Open-Label Extension Study of OCV-501 in Acute Myeloid Leukemia
jRCT2080221606Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2011
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OCV-501 in acute myeloid leukemia (AML), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety and tolerability of OCV-501. Started Oct 2011; status: completed.
02
Drugs
OCV-501
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2080221606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221606.